{"nctId":"NCT02719327","briefTitle":"Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid","startDateStruct":{"date":"2017-06-08","type":"ACTUAL"},"conditions":["Alzheimer's Disease"],"count":131,"armGroups":[{"label":"icosapent ethyl (IPE)","type":"EXPERIMENTAL","interventionNames":["Drug: icosapent ethyl (IPE)"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: gel cap placebo"]}],"interventions":[{"name":"icosapent ethyl (IPE)","otherNames":["Vascepa"]},{"name":"gel cap placebo","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* United States Veteran eligible for VA care\n* Age 50-75 years, inclusive\n* Cognitively healthy\n\nExclusion Criteria:\n\n* Dementia or mild cognitive impairment on screening evaluation\n* Current use of fish oil supplements (requires 3 month wash-out period)\n* Active liver disease with AST or ALT greater than twice the upper limit of normal\n* Elevated creatine kinase greater than twice the upper limit of normal\n* Prior adverse reaction to statins or fish oil\n* Pregnant, nursing, or pregnancy planned\n* Use of medications that interact with icosapent ethyl\n* Current use of anticoagulants\n* Known hypersensitivity to fish and/or shellfish\n* Current use of other investigational drug\n* History of significant atherosclerotic cardiovascular disease or diabetes mellitus\n* Low-density lipoprotein (LDL) cholesterol \\> or =190 mg/dL or \\<80 mg/dL\n* Triglycerides \\> or = 500 mg/dL\n* Creatinine \\>1.8 mg/dL\n* Previous lumbar surgery with contraindication to lumbar puncture\n* Claustrophobia requiring sedation for MRI\n* Pacemaker or other contraindication for MRI\n* Consumption of \\>200 mg per day omega-3 fatty acids in diet","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Regional Cerebral Blood Flow Using Arterial Spin-labeling MRI","description":"For the primary outcome we chose an anatomical region, posterior cingulate gyrus, that aligned with statistical region of interest sensitive to changes in cerebral blood flow in cognitively-unimpaired adults at risk for Alzheimer's disease. Brain blood flow was averaged across the right and left posterior cingulate gyrus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":"14.6"},{"groupId":"OG001","value":"54.5","spread":"14.1"}]}]}]},{"type":"SECONDARY","title":"Cerebrospinal Fluid (CSF) Biomarkers of Alzheimer's Disease","description":"CSF beta-amyloid-42, total tau, and phosphorylated tau-181 (Roche Cobas Elecsys e611). Lower CSF beta-amyloid-42 and higher phosphorylated tau-181 or total tau are associated with risk for Alzheimer's disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1281.7","spread":"558.5"},{"groupId":"OG001","value":"1244.6","spread":"607.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":"8.13"},{"groupId":"OG001","value":"18.8","spread":"5.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218.2","spread":"83.6"},{"groupId":"OG001","value":"208.0","spread":"63.7"}]}]}]},{"type":"SECONDARY","title":"Cognitive Performance","description":"Alzheimer's Disease Cooperative Study Preclinical Alzheimer's Cognitive Composite (ADCS-PACC). Composite scores at each time point are standardize to baseline values such that at baseline the mean=0 and the standard deviation = 1. Standardized scores range from -3.15 to 3.09. Higher scores indicate better cognition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.455","spread":"1.22"},{"groupId":"OG001","value":"0.611","spread":"1.10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":63},"commonTop":["Muscle pain","Headache","Accident","Cancer","Abscess"]}}}